Sign in
Active, not recruitingEarly phase 1

Vaccine Pandemic Preparedness Through Airway Immunology Characterization

Key facts

Who runs it
Copenhagen Respiratory Research
Where
Denmark and United Kingdom2 sites in 2 countriesChoose a country to see its sites
Status
Active, not recruiting
Phase
Early phase 1
People taking part
60 people, planned
Started
19 May 2025
Expected to end
31 Oct 2032
Type of study
Interventional, 2 groups
Treatments tested
  • Vaxigripetra
  • Flumist
Record updated
6 November 2026

Who can take part

Age
18 years to 49 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Healthy individuals (Charlson´s co-morbidity index :0, and investigator judged as healthy)
  • Age: 18-49 years
  • Total IgG levels in normal range (discretion of investigator according to local lab)
  • Total IgA levels (discretion of investigator according to local lab)
  • Undetectable HAI titres to the H3N2 component of the vaccines*
  • Normal CD4+ and CD8+ T-cell and normal B-cell counts
  • Reference levels from ISO-15189 accredited T-, B- and NK-cell count routine analyses will be applied; If <20% of the first 100 screened persons apply to this criterion, this will be changed to a specific cut off based on the lowest quartile level of HAI titres to the H3N2 component of these 100 screened persons

Who cannot take part

  • Any allergies to components of or contraindication for Vaxigriptetra® or Flumist® incl. previous severe adverse reactions to influenza vaccinations or components of the vaccines
  • Use of immunosuppressive drugs* within the past 6 months or who are currently using them
  • Have an acute illness, including an oral temperature ≥ 38°C, within 3 days prior to vaccination
  • Have received any vaccines, including live-attenuated vaccines within 4 weeks before inclusion, or plan receipt of such vaccines within 30 days following the inclusion
  • Inability to provide written informed consent; defined as: Azathioprin, methotrexate, cyclophosphamide, basiliximab, belimumab, anifrolumab, alemtuzumab, rituximab, mycophenolat, calcineurin inhibitors (ciclosporin, voclosporin and tacrolimus), mTOR inhibitors (everolimus and sirolimus), prednisolone (or any corticosteroid in doses above the equivalent of 5 mg prednisolone), TNF-α inhibitors (such as infliximab), anti-thymocyte globulin
  • Any known malignant neoplasm within 5 years (except basal carcinoma of the skin)
  • Severe mental illness or linguistic issues which significantly impedes cooperation
  • Laboratory-confirmed influenza infection during the past year documented by a positive PCR test in the Danish Microbiological database or anamnestic reported influenza infection in the same period
  • HIV, HBV, HCV laboratory confirmed active infection at screening visit
  • Active smoker
  • BMI > 35 kg/m2
  • Women of childbearing potential not using safe contraception, or who are pregnant, or breast-feeding

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study aims to compare the effectiveness of live attenuated influenza vaccines (LAIV) and intramuscular-inactivated vaccines (IIV) in healthy individuals aged 18-49. It will investigate cellular and humoral responses, identify immunological markers for targeted vaccine improvement, and establish a collaborative platform for accelerated immunological and clinical vaccine research.

The 2 groups in the trial

  • VaxigripetraTreatment being tested

    This arm will receive 1 dose of 0.5 mL Vaxigripetra (intra-muscular injection) and 1 dose of 0.2 mL placebo (nasal, 1 spray in each nostril).

  • FlumistTreatment being tested

    1 dose of 0.2 mL Flumist (nasal, 1 spray in each nostril) and 1 dose of 0.5 mL placebo (intra-muscular injection).

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
In-depth Immunological Analysis of Airway Immunity Following Nasal Live Attenuated and Intramuscular Influenza Vaccine
Record updated
6 November 2026